Advertisement.
Advertisement.
Advertisement
Advertisement.
MRUS Merus N.V
907
| Market Cap | $3.66B |
| Volume | 263,758.00 |
| 52-Wk High | $61.61 |
| 52-Wk Low | $19.81 |
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga•2 months ago
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy...
Share to Feed
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates PR Newswire VANCOUVER, BC...
PR Newswire•2 months ago
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...
PR Newswire•2 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Globe Newswire•4 months ago
Shares of Merus (NASDAQ:MRUS - Get Free Report) have been assigned an average recommendation of "Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports...
Zolmax•4 months ago
This indicator may be signaling MRUS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks•4 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly•4 months ago
Shares of Merus (NASDAQ:MRUS Get Free Report) fell 4% on Monday . The stock traded as low as $44.00 and last traded at $44.09. 69,244 shares traded hands during mid-day trading, a decline of...
Ticker Report•4 months ago
Merus (NASDAQ:MRUS Get Free Report) and CohBar (NASDAQ:CWBR Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based...
Ticker Report•4 months ago
This is a signal that MRUS's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
Tickeron - Stocks•4 months ago